{"url_path":"/sec/sxtpw/8-k/2026-05-18/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-18","source_url":"https://www.sec.gov/Archives/edgar/data/1946563/0001213900-26-058495-index.html","accession_number":"0001213900-26-058495","cik":"0001946563","ticker":"SXTP","issuer_name":"60 DEGREES PHARMACEUTICALS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1946563/0001213900-26-058495-index.html","primary_entity_key":"0001946563","primary_entity_name":"60 DEGREES PHARMACEUTICALS, INC."},"word_count":346,"has_tables":true,"body_markdown":"false\n0001946563\nDC\n\n0001946563\n\n2026-05-13\n2026-05-13\n\n0001946563\n\nSXTP:CommonStockParValue0.0001PerShareMember\n\n2026-05-13\n2026-05-13\n\n0001946563\n\nSXTP:WarrantsEachWarrantToPurchaseOneShareOfCommonStockMember\n\n2026-05-13\n2026-05-13\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE\nCOMMISSION**\n\n**WASHINGTON, D.C. 20549**\n\n \n\n**FORM 8-K**\n\n \n\n**CURRENT REPORT**\n\n**PURSUANT TO SECTION\n13 OR 15(d)**\n\n**OF THE SECURITIES EXCHANGE\nACT OF 1934**\n\n \n\nDate of Report (Date of\nearliest event reported): May 13, 2026\n\n \n\n**60 DEGREES PHARMACEUTICALS,\nINC.**\n\n(Exact name of registrant\nas specified in its charter)\n\n \n\n**Delaware**\n \n**001-41719**\n \n**45-2406880**\n\n(State or other jurisdiction\nof Incorporation)\n \n(Commission File Number)\n \n(IRS Employer\nIdentification Number)\n\n \n\n**1025 Connecticut Avenue NW Suite 1000,**\n\n**Washington****,\nD.C.**\n\n \n**20036**\n\n(Address of registrant’s principal executive office)\n \n(Zip code)\n\n** **\n\n**(202) 327-5422**\n\n(Registrant’s telephone\nnumber, including area code)\n\n \n\n**Not Applicable**\n\n(Former name or former\naddress, if changed since last report)\n\n \n\nCheck the appropriate\nbox below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following\nprovisions (see General Instruction A.2. below):\n\n \n\n☐\nWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n \n\n☐\nSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n \n\n☐\nPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n \n\n☐\nPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\n \n\nSecurities registered\npursuant to Section 12(b) of the Act:\n\n \n\n**Title of each class**\n \n**Trading symbol(s)**\n \n**Name of each exchange on which registered**\n\nCommon Stock, par value $0.0001 per share\n \nSXTP\n \nThe Nasdaq Stock Market LLC\n\nWarrants, each warrant to purchase one share of Common Stock\n \nSXTPW\n \nThe Nasdaq Stock Market LLC\n\n \n\nIndicate by check mark\nwhether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter)\nor Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).\n\n \n\nEmerging\ngrowth company ☒\n\n \n\nIf an emerging growth\ncompany, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or\nrevised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐"}